George Jackowski - Academia.edu (original) (raw)

Papers by George Jackowski

Arteriosclerosis, Thrombosis, and Vascular Biology, 2013

Introduction Treatments with Omega-3 (OM3) formulations have been suggested to have cardio-protec... more Introduction Treatments with Omega-3 (OM3) formulations have been suggested to have cardio-protective effects. A strong association of high plasma OM3 levels has been correlated with reduced risk of sudden death and “risk quartiles” based upon OM3 levels, have been previously described. However, systematic studies describing the extent of OM3 deficiency, it’s correction by intervention, and improvement in CVD risk factors are lacking. Our study is the first to determine dietary levels of OM3 in plasma and in red blood cells using Omega-Score and Omega-3 Index diagnostics, improvement after treatment with a proprietary “>90%-pure OM3 preparation with a 6:1 EPA (eicosapentaenoic acid): DHA (docosapentaenoic acid) ratio” (6:1-OM3), and the concomitant beneficial effects on CVD risk factors in patients with high triglycerides (TG 200-500mg/dL). Hypothesis CVD patients are nutritionally deficient in OM3 fatty acids, and through treatment with 6:1-OM3, such deficiency can be corrected,...

Arteriosclerosis, Thrombosis, and Vascular Biology, 2014

Background: Growing evidence supports the value of maintaining a diet rich in omega-3 polyunsatur... more Background: Growing evidence supports the value of maintaining a diet rich in omega-3 polyunsaturated fatty acids (PUFA) to achieve longevity of cardiovascular health, and prevent sudden death. Omega-3 deficiency (OM3D) is highly prevalent in the US and contributes to 84,000 deaths/year. To identify patients at risk with OM3D, two laboratory tests are available, including the Omega-Score (OS - whole blood), as well as the Omega-3 Index (OI - red blood cell membrane), that measure omega-3 blood levels. Omega-Score or OI levels <6.1% suggest OM3D. Here we report on the dietary omega-3 status of Canadians, including those with CVD risk factors, through a comparative analysis of the OS vs. OI both pre- and post-treatment with a unique omega-3 formulation. Methods: Open label study of 143 study subjects enrolled for baseline omega-3 deficiency assessment, of which 63 subjects were scheduled to receive a 4 g/day regimen of a highly purified (>90%) omega-3 formulation (2720 mg/day of...

La presente invention concerne une composition et un procede de traitement utilisant une associat... more La presente invention concerne une composition et un procede de traitement utilisant une association de statines (ou inhibiteurs de la HMG-CoA reductase), une classe de medicaments utilises pour baisser la cholesterolemie par inhibition de l'enzyme HMG-CoA reductase, avec des melanges d'une preparation d'acides gras omega-3 contenant environ 90 % ou plus d'acides gras omega-3 en poids comprenant une combinaison d'acide eicosapentaenoique (EPA), d'acide docosapentaenoique (DPA) et d'acide docosahexaenoique (DHA) selon un rapport ponderal EPA/DHA allant de 5,7 a 6,3, la somme d'EPA, de DHA et de DPA representant environ 82 % en poids de la preparation totale et environ 92 % de la teneur totale en acides gras omega-3 de la composition. EPA + DHA representent environ 80 % de la preparation totale et environ 89 % de la teneur totale en acides gras omega-3 de la composition. La preparation peut en outre contenir des quantites specifiques d'acide arachid...

It describes a method for diagnosing Alzheimer's dementia (AD). The method consists in direct... more It describes a method for diagnosing Alzheimer's dementia (AD). The method consists in directly detected whether there is a glutamine synthetase biochemical marker in bodily fluid, such as a human body, especially blood or blood products exist. This detection method is carried out by immunoassay incorporating the antibody specific for glutamine synthetase human. Further, a description will be given of how to distinguish between AD and non-Alzheimer's dementia -AD.

Journal of Nutritional Science, 2015

The aim of the present study was to evaluate the oxidation status of North Americann-3 (omega-3) ... more The aim of the present study was to evaluate the oxidation status of North Americann-3 (omega-3) PUFA nutritional supplements commercially available in Canada and evaluate the influence of product formulation and delivery form on oxidative safety. A total of 171 North American over-the-countern-3 PUFA nutritional supplements were analysed for oxidation safety. Primary and secondary oxidation and total oxidation (TOTOX) were determined using the American Oil Chemists’ Society (AOCS) procedures. Comparisons between supplements’ final forms, oil source andn-3 PUFA concentration quartiles, as measures of product formulations and delivery forms, were compared using ANOVA. Of the products successfully tested, 50 % exceeded the voluntary recommended levels for markers of oxidation. Another 18 % of products were approaching the limits with 1–3 years before expiration. Encapsulated products without flavour additives had significantly lower secondary and TOTOX levels than bulk oils and flavou...

The instant invention involves the use of a combination of preparatory steps in conjunction with ... more The instant invention involves the use of a combination of preparatory steps in conjunction with mass spectroscopy and time-of-flight detection procedures to maximize the diversity of biopolymers which are verifiable within a particular sample. The cohort of biopolymers verified within such a sample is then viewed with reference to their ability to evidence at least one particular disease state; thereby enabling a diagnostician to gain the ability to characterize either the presence or absence of at least one disease state relative to recognition of the presence and/or the absence of the biopolymer, predict disease risk assessment, and develop therapeutic avenues against the disease.

Molecular and Cellular Biochemistry, 2014

Low blood levels of long chain omega-3 polyunsaturated fatty acids (LC n-3 PUFA) have been report... more Low blood levels of long chain omega-3 polyunsaturated fatty acids (LC n-3 PUFA) have been reported to be associated with increased risk for cardiovascular disease (CVD) deaths. Systematic studies measuring LC n-3 PUFA blood levels (pre and post-treatment) in defined subjects, and monitoring the correction of nutritional deficiency with a pure LC n-3 PUFA formulation in sufficient doses, while monitoring CVD risk factors are lacking. We tested the efficacy of a novel LC n-3 PUFA Medical Food formulation (VASCAZEN Ò , [ 90 % pure with a 6:1 eicosapentaenoic acid-(EPA):docosahexaenoic acid-(DHA) ratio; 6:1-OM3), to correct such deficiency and determine the concomitant effects on lipid profiles. Of 655 subjects screened, 89 % were LC n-3 PUFA deficient (Omega-Score, (OS) = blood EPA ? DHA ? Docosapentaenoic acid \ 6.1 %). From these, a study was conducted on 110 ambulatory cardiovascular subjects. Placebo: corn oil. Primary endpoint: change in OS. Secondary endpoint: changes in blood lipid profiles. At 8 weeks of treatment with 6:1-OM3 (4 g/day), placebo-adjusted median OS levels (n = 56) significantly improved (132 %, P \ 0.0001) with a decrease in AA (arachidonic acid): EPA ratio (82 %, P \ 0.0001). In hypertriglyceridemic subjects (TG 2.26-5.65 mmol/L), HDL-C improved (9 %, P = 0.0069), TG-reduced (48 %, P \ 0.0001), and VLDL-C reduced (30 %, P = 0.0023), without significantly affecting LDL-C levels. This study confirms that LC n-3 PUFA deficiency is prevalent in the US population, and its correction with 6:1-OM3 in CVD subjects improves lipid profiles. The purity, EPA:DHA ratio and dose are determinant factors for optimal efficacy of a formulation in reducing CVD risk factors.

Protein Expression and Purification, 1996

The adult isoform of human cardiac troponin T (TnT) contains 288 amino acids, 14 of which (4.9%) ... more The adult isoform of human cardiac troponin T (TnT) contains 288 amino acids, 14 of which (4.9%) are cDNA revealed that these isoforms are generated by encoded by the rarely used arginine codons (12 AGG, alternative splicing of a single gene localized to 1q32 2 AGA) in Escherichia coli genes. To generate sufficient (4)(5). Recent clinical studies have found that serum quantity of TnT protein for antibody production, we cardiac TnT is a sensitive and specific marker for myocloned the corresponding cDNA and expressed it in E. cardial cell damage and that its detection can be used coli. A low-level expression of TnT that comprised only to identify, among patients with unstable angina, those about 1% of total cell protein was initially observed at risk of myocardial infarction (6,7). In order to generate human cardiac TnT protein for pairs of consecutive AGG codons (AGG 165 AGG 166 and antibody production, we cloned the cDNA encoding the AGG 215 AGG 216 ) in the cDNA was suspected to be the adult isoform of the TnT and expressed it in Eschemain cause for this low-level expression. These two richia coli. It has previously been shown that E. coli pairs of consecutive AGG codons were successively regenes encoding abundant proteins more frequently use placed with the major synonymous codon CGT by sitea subset of synonymous codons, the so-called major (or directed mutagenesis. As suspected, a 10-fold increase common) codons, than those encoding less abundant in TnT expression was obtained when one pair of the proteins. There exists a strong positive correlation berare arginine codons was replaced and a 40-fold intween the gene expression level and the degree of bicrease was achieved when both pairs of the rare coased codon usage (8,9). Consistent with this is the finddons were replaced. Our finding demonstrates the iming that systematic replacements of infrequently used portance of consecutive rare codons in the supprescodons (rare codons) with synonymous major ones in sion of high-level expression of heterologous proteins heterologous genes, either for the entire protein coding in E. coli and suggests that in order to maximize proregion or for a substantial portion of it, result in sigtein expression, a similar approach may be taken with nificant increases in the expression of corresponding other genes which contain consecutive rare codons.

Journal of the American College of Cardiology, 1998

Journal of Molecular and Cellular Cardiology, 1992

To explore the mechanisms regulating expression of ventricular myosin light chain 1, the human ge... more To explore the mechanisms regulating expression of ventricular myosin light chain 1, the human gene including 5'-flanking DNA was cloned and characterized by Southern blot and restriction mapping. A 2 kb 5'-flanking DNA was sequenced and linked to a chloramphenicol acetyltransferase reporter gene. The constructs then were transfected into cultured human and rat cardiomyocytes as well as rat aortic endothelial cells. Deletion analysis of constructs revealed that the basal promoter sequences, which were located within 62 base pairs of the cap site, could direct high levels of chloramphenicol acetyltransferase gene expression in the cardiomyocytes and endothelial cells. The region between -62 to -312 base pairs strongly repressed the chloramphenicol acetyltransferase gene expression in the cardiomyocytes and endothelial cells. Positive elements were found between -312 and -2000 base pairs of the cap site. These results are indicative, among other possibilities, that the human ventricular myosin light chain 1 gene is turned on in cardiomyocytes by the presence of trans-acting factors that are bound to upstream positive elements and is turned off in non-muscle cells by the presence of repressor-binding proteins. But this mechanism remains to be established.

Clinical Biochemistry, 1995